公开(公告)号：US20060121128A1

公开(公告)日：2006-06-08

申请号：US10542555

申请日：2004-01-20

申请人： Erik Schwiebert ,  Akos Zsembery

发明人： Erik Schwiebert ,  Akos Zsembery

IPC分类号： A61K33/32

CPC分类号： A61K31/7088 ,  A61K31/315 ,  A61K31/7072 ,  A61K33/30 ,  Y10S514/826 ,  Y10S514/851 ,  Y10S514/924 ,  A61K2300/00

摘要： This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).

摘要翻译： 本发明一般涉及在哺乳动物细胞中增加胞质Ca 2+水平的方法，包括接触P2X受体Ca 2+ 2 +进入通道或任何和所有其它Ca 2+ + 有效量的小分子的细胞上的入口通道或机制，以及包含递送系统中的小分子的组合物。 本发明作为治疗气道疾病（如囊性纤维化和哮喘），肺和气道疾病（如常见感冒病原体或过敏原引起的疾病），肾脏疾病和肾脏疾病的方法具有广泛适用性 高血压疾病（如多囊肾病和盐敏感性高血压综合征）和内分泌疾病（如糖尿病）。

公开(公告)号：US20090175800A1

公开(公告)日：2009-07-09

申请号：US12404942

申请日：2009-03-16

申请人： Erik Schwiebert ,  Akos Zsembery

发明人： Erik Schwiebert ,  Akos Zsembery

IPC分类号： A61K9/12 ,  A61K33/30 ,  G01N33/53 ,  A61P11/06

CPC分类号： A61K31/7088 ,  A61K31/315 ,  A61K31/7072 ,  A61K33/30 ,  Y10S514/826 ,  Y10S514/851 ,  Y10S514/924 ,  A61K2300/00

摘要： This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).

摘要翻译： 本发明一般涉及增加哺乳动物细胞中胞质Ca 2+水平的方法，其包括使P2X受体Ca 2+进入通道或细胞中任何和所有其它Ca 2+进入通道或机制与有效量的小分子接触，以及包含小分子 分子在递送系统中。 本发明作为治疗气道疾病（如囊性纤维化和哮喘），肺和气道疾病（如常见感冒病原体或过敏原引起的疾病），肾脏疾病和肾脏疾病的方法具有广泛适用性 高血压疾病（如多囊肾病和盐敏感性高血压综合征）和内分泌疾病（如糖尿病）。

公开(公告)号：US07524517B2

公开(公告)日：2009-04-28

申请号：US10542555

申请日：2004-01-20

申请人： Erik Schwiebert ,  Akos Zsembery

发明人： Erik Schwiebert ,  Akos Zsembery

IPC分类号： A61K33/30 ,  A61K31/315 ,  A61K31/7076 ,  A61P11/00 ,  A61P11/06

CPC分类号： A61K31/7088 ,  A61K31/315 ,  A61K31/7072 ,  A61K33/30 ,  Y10S514/826 ,  Y10S514/851 ,  Y10S514/924 ,  A61K2300/00

摘要： This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule in a delivery system. The invention has broad applicability in the pharmaceutical industry as a method of treating airway diseases (such as cystic fibrosis and asthma), ailments of the lung and airways (such as those caused by common cold pathogens or allergens in allergy), kidney diseases and renal hypertensive disorders (such as polycystic kidney disease and salt-sensitive hypertension syndromes), and endocrine disorders (such as diabetes).

摘要翻译： 本发明一般涉及增加哺乳动物细胞中胞质Ca 2+水平的方法，其包括使P2X受体Ca 2+进入通道或细胞中任何和所有其它Ca 2+进入通道或机制与有效量的小分子接触，以及包含小分子 分子在递送系统中。 本发明作为治疗气道疾病（如囊性纤维化和哮喘），肺和气道疾病（如常见感冒病原体或过敏原引起的疾病），肾脏疾病和肾脏疾病的方法具有广泛适用性 高血压疾病（如多囊肾病和盐敏感性高血压综合征）和内分泌疾病（如糖尿病）。